Brokerages Set Qiagen NV (QGEN) PT at $26.00
Qiagen NV (NASDAQ:QGEN) has earned an average recommendation of “Hold” from the sixteen analysts that are presently covering the firm. Eight investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.00.
QGEN has been the topic of a number of research reports. Commerzbank AG restated a “buy” rating on shares of Qiagen NV in a research note on Friday, September 9th. Zacks Investment Research raised Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Wednesday, September 14th. DZ Bank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Monday, September 12th. Morgan Stanley set a $30.00 target price on Qiagen NV and gave the company a “buy” rating in a report on Sunday, September 11th. Finally, TheStreet raised Qiagen NV from a “hold” rating to a “buy” rating in a report on Friday, July 29th.
Qiagen NV (NASDAQ:QGEN) opened at 27.51 on Monday. The company has a market cap of $6.44 billion, a PE ratio of 55.02 and a beta of 1.07. Qiagen NV has a 12-month low of $19.94 and a 12-month high of $28.50. The stock has a 50 day moving average of $26.38 and a 200-day moving average of $24.39.
Qiagen NV (NASDAQ:QGEN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.01. Qiagen NV had a return on equity of 9.34% and a net margin of 8.96%. The business had revenue of $338.70 million for the quarter, compared to analysts’ expectations of $335.46 million. During the same period in the previous year, the business posted $0.27 EPS. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. On average, equities research analysts anticipate that Qiagen NV will post $1.06 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Qiagen NV during the second quarter valued at about $116,000. First Mercantile Trust Co. purchased a new stake in shares of Qiagen NV during the second quarter valued at about $126,000. Riverhead Capital Management LLC raised its stake in shares of Qiagen NV by 402.2% in the third quarter. Riverhead Capital Management LLC now owns 5,800 shares of the company’s stock valued at $159,000 after buying an additional 4,645 shares in the last quarter. Societe Generale purchased a new stake in shares of Qiagen NV during the second quarter valued at about $152,000. Finally, SG Americas Securities LLC raised its stake in shares of Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock valued at $152,000 after buying an additional 629 shares in the last quarter. 58.80% of the stock is owned by institutional investors and hedge funds.
Qiagen NV Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Stock Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related stocks with our FREE daily email newsletter.